Multiple SclerosisNCT04855825
Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS
A study testing Robotic Exoskeleton Rehabilitation and Conventional Gait Therapy in people with Multiple Sclerosis and Gait Disorders, Neurologic, run by Kessler Foundation at 1 site in United States.
Trial summary
The purpose of this research study is to evaluate the usefulness of a wearable robotic exoskeleton device (Ekso-GT), to improve learning and memory, and gait therapy in persons with walking disability due to Multiple Sclerosis. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Multiple Sclerosis, Gait Disorders, Neurologic, Motility Disorder
- What is being tested?
- Robotic Exoskeleton Rehabilitation and Conventional Gait Therapy
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteUnited States
- Study dates
- 5 Oct 2017to 30 Dec 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Be diagnosed with multiple sclerosis.
- Be determined by the study staff to have moderate to severe difficulty walking but still be able to walk while using the robotic exoskeleton.
- Have some difficulty thinking and problem solving as determined by my performance on a special test that I will take during the screening visit.
- Be between the ages of 18 and 75.
- Be free from flair ups of my MS Symptoms for at least one month prior to testing.
- Discuss with study staff how to maintain a constant level of my spasticity medication (for example baclofen) throughout the study.
Show all 15Show fewer
- Be able to walk (with the use of one or more assistive device if needed).
- Have English as my primary language.
- Be able to physically fit into the exoskeleton device: height between 60 and 76", weight under 220 lbs.
- Be able to tolerate upright standing for 30 minutes with assistance if needed.
- Have normal joint range of motion for walking as determined by study staff.
- Have sufficient strength to use the hemiwalker, bilateral canes or walker while wearing the RE.
- Have stable blood pressure.
- Be willing and able to give informed consent.
- Be able and willing to comply with study procedures and follow directions and commands, verbal instructions, and follow-up requirements.
Who cannot join
- Have a history of head injury, stroke, seizures, or any other significant neurological history other than MS.
- Have a high degree of difficulty in thinking and problem solving that prevents me from participating in the study as determined by my performance on a special test taken during the screening visit.
- Be currently taking steroids, benzodiazepines, antipsychotics, and/or neuroleptics as determined by study staff review of my medications.
- Be pregnant.
- Be completely reliant on a wheelchair.
- Have joint contracture or spasticity of any limb that limits normal range of motion during walking with assistive devices as determined by study staff.
Show all 14Show fewer
- Have skin issues that would prevent wearing the RE.
- Have pressure sore stage 2 or higher located in an area that would negatively affect weight bearing, harness fit, or therapist assistance.
- Have orthopedic issues or history that will interfere with walking or limit the range of motion of the lower limbs (e.g., knee replacement, inflammation)
- Have been hospitalized for heart attack, heart surgery or acute heart failure within 3 months of enrollment in study.
- Have any other medical conditions that my doctor or physical therapist feels would affect my ability to use the robotic device.
- Have a pacemaker or other implanted electrical device, brain stimulator, aneurysm clip (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and internal hearing aids [cochlear implants]), permanent eyeliner, implanted delivery pumps, or shrapnel fragments.
- Have dental implants- I should discuss any dental implants with the investigators.
- Have been told by my doctor that it is unsafe for me to have a regular MRI as part of my medical care.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Kessler Foundation
West Orange, New Jersey, 07052
Ghaith J Androwis, Ph.D., 973-324-3565, gandrowis@kesslerfoundation.org
About this study
The purpose of this research study is to evaluate the usefulness of a wearable robotic exoskeleton device (Ekso-GT), to improve learning and memory, and gait therapy in persons with walking disability due to Multiple Sclerosis. The study will evaluate the mobility, learning and memory, and walking abilities of individuals with multiple sclerosis who went through the traditional as compared to others who used the robotic exoskeleton as part of their therapy.
- Being tested
- Robotic Exoskeleton Rehabilitation, Conventional Gait Therapy
- Medical subject headings
- Multiple Sclerosis, Gait Disorders, Neurologic, Cognitive Dysfunction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Robotic Exoskeleton RehabilitationDevice
Participants will be randomly assigned to one of the two groups. Each participant will receive 8 sessions of gait rehabilitation and therapy via traditional therapy techniques of using the robotic exoskeleton. This training will be provided by a licensed physical therapist.
Conventional Gait TherapyOther
Participants will be randomly assigned to one of the two groups. Each participant will receive 8 sessions of gait rehabilitation and therapy via traditional therapy techniques of using the robotic exoskeleton. This training will be provided by a licensed physical therapist.
| Study group | Role | What they receive |
|---|---|---|
| Robotic Exoskeleton Therapy | Experimental | Gait rehabilitation provided using a wearable robotic exoskeleton Receives: Device: Robotic Exoskeleton Rehabilitation |
| Conventional Gait Therapy | Active comparator | Gait rehabilitation provided using traditional gait therapy under the supervision of a licensed PT Receives: Other: Conventional Gait Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Distance walked in a specific time duration
The distance walked (meters) in 6 minutes is measured. This is following the 6-minute walk test (6MWT) procedure to measure walking endurance. The 6MWT is is a valid and reliable test of endurance walking performance in persons with MS.
Participants are instructed to walk as fast and as far as possible for 6 minutes within a single corridor and performing 180° turns.
Measured: approximately 12 weeks
Neuropsychological measures of thinking
Processing speed and cognition outcomes, including: The Symbol Digit Modalities Test (SDMT) represents the primary CPS outcome in the current proposal. This test involves the conversion of a set of simple geometric designs into an oral response. It has been demonstrated to be sensitive to the presence of brain damage in numerous studies. The SDMT requires the examinee to substitute a number for a randomized presentation of a geometric figure. The appropriate number is shown in a key containing the Arabic numbers 1 through 9, each paired with a different geometric figure. The total number of correct responses in 90 seconds is the primary outcome of the SDMT.
Measured: approximately 12 weeks
Brain scans
Participants will undergo neuroimaging scans of the brain to acquire structural imaging of the brain using Magnetic resonance imaging (MRI).
The MRI instrument that will be used is an FDA-approved Siemens Skyra 3T clinical imager housed in the Rocco Ortenzio Neuroimaging Center at Kessler Foundation.
Measured: approximately 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Apr 2021
- Study start5 Oct 2017
- Primary completion30 Dec 2027 (estimated)
- Study completion30 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Kessler Foundation
- Sponsor type
- University, hospital or other
- Collaborators
- Kessler Institute for Rehabilitation
- Responsible party
- Principal investigator, Ghaith J. Androwis, Ph.D., Kessler Foundation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04855825
- Sponsor's protocol ID
- D-983-17
- Status last verified
- Nov 2025
- First submitted
- 18 Jun 2018
- Last updated
- 24 Nov 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Undecided